Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Study of PF-04965842 Effect on Dabigatran Pharmacokinetics in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04965842
Drug: Dabigatran

First Posted Date: 2018-11-15

Last Posted Date: 2020-02-28

Lead Sponsor: Pfizer

Target Recruit Count: 20

Registration Number: NCT03742336

Locations: 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium

PF-06651600 for the Treatment of Alopecia Areata

Phase 2

Completed

Conditions: Alopecia Areata

Interventions: Drug: PF-06651600 Induction Dose
Drug: PF-06651600 Maintenance Dose #1
Drug: PF-06651600 Maintenance Dose #2
Drug: PF-06651600 Maintenance Dose #3
Drug: Placebo

First Posted Date: 2018-11-07

Last Posted Date: 2022-02-24

Lead Sponsor: Pfizer

Target Recruit Count: 718

Registration Number: NCT03732807

Locations: 🇺🇸
Mosaic Dermatology, Beverly Hills, California, United States
🇺🇸
Dermatology Specialists, Inc., Murrieta, California, United States
🇺🇸
University of California, Irvine, Department of Dermatology, Dermatology Clinical Research Center, Irvine, California, United States

and more 150 locations

Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults

Phase 2

Completed

Conditions: Migraine

Interventions: Drug: Rimegepant
Drug: Placebo

First Posted Date: 2018-11-06

Last Posted Date: 2024-06-07

Lead Sponsor: Pfizer

Target Recruit Count: 1590

Registration Number: NCT03732638

Locations: 🇺🇸
Cedar Crosse Research Center, Chicago, Illinois, United States
🇺🇸
Oklahoma Headache Center, Norman, Oklahoma, United States
🇺🇸
Clinical Investigation Specialists, Inc., Kenosha, Wisconsin, United States

and more 84 locations

A Study of Duloxetine Hydrochloride Hard Gelatinous Capsule Compared To Cymbalta

Phase 4

Withdrawn

Conditions: Healthy

Interventions: Drug: Duloxetine Hydrochloride Capsules
Drug: Cymbalta Capsules

First Posted Date: 2018-11-02

Last Posted Date: 2019-10-04

Lead Sponsor: Pfizer

Registration Number: NCT03729284

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

Phase 4

Completed

Conditions: Pharmacokinetics
Safety
ECG

Interventions: Drug: Gemtuzumab Ozogamicin

First Posted Date: 2018-11-01

Last Posted Date: 2022-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 51

Registration Number: NCT03727750

Locations: 🇭🇺
Semmelweis Egyetem I.sz Belgyogyaszati Klinika, Hematologiai Osztaly, Budapest, Hungary
🇬🇧
The Royal Bournemouth and Christchurch NHS Foundation Trust, Bournemouth, Dorset, United Kingdom
🇺🇸
Brody School of Medicine at East Carolina University, Greenville, North Carolina, United States

and more 21 locations

Hepatic Impairment Study for Lorlatinib in Cancer Patients

Phase 1

Terminated

Conditions: Advanced Cancers

Interventions: Drug: lorlatinib

First Posted Date: 2018-10-31

Last Posted Date: 2024-06-21

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT03726333

Locations: 🇺🇸
University of Colorado Denver CTO (CTRC), Aurora, Colorado, United States
🇺🇸
University of Colorado Hospital, Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States
🇺🇸
University of Colorado Hospital, Anschutz Inpatient Pavilion (AIP), Aurora, Colorado, United States

and more 7 locations

Actual Use and Compliance Study Of Ibuprofen 600 Mg Immediate Release/Extended Release Tablets In At-Risk OTC Consumers

Phase 3

Terminated

Conditions: Pain

Interventions: Drug: Ibuprofen 600 mg Immediate Release/Extended Release Caplet

First Posted Date: 2018-10-26

Last Posted Date: 2021-09-24

Lead Sponsor: Pfizer

Target Recruit Count: 613

Registration Number: NCT03722238

Locations: 🇺🇸
Mills Pharmacy at Bluff Park, Hoover, Alabama, United States
🇺🇸
ACACIA Apothecary and Wellness, Tucson, Arizona, United States
🇺🇸
Summerfield Pharmacy, Riverview, Florida, United States

and more 24 locations

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

Phase 3

Completed

Conditions: Dermatitis, Atopic
Eczema
Skin Diseases
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Dermatitis
Hypersensitivity
Genetic Diseases, Inborn
Skin Diseases, Genetic
Immune System Diseases

Interventions: Drug: PF-04965842 100 mg
Drug: PF-04965842 200 mg
Drug: Dupilumab
Drug: Injectable Placebo
Drug: Oral Placebo

First Posted Date: 2018-10-25

Last Posted Date: 2021-01-19

Lead Sponsor: Pfizer

Target Recruit Count: 838

Registration Number: NCT03720470

Locations: 🇺🇸
Moonshine Research Center, Inc., Doral, Florida, United States
🇺🇸
PMG Research of Raleigh, LLC d/b/a PMG Research of Cary, Cary, North Carolina, United States
🇨🇦
Toronto Research Centre, Toronto, Ontario, Canada

and more 210 locations

Descriptive Observational Study ALK-2016-CPHG

Completed

Conditions: NSCLC
ALK Gene Rearrangement or ROS1 Gene Rearrangement
Crizotinib

First Posted Date: 2018-10-24

Last Posted Date: 2021-09-28

Lead Sponsor: Pfizer

Target Recruit Count: 71

Registration Number: NCT03718117

Locations: 🇫🇷
Centre Hospitalier General Beziers, Service De Pneumologie, Beziers, France
🇫🇷
Centre Hospitalier Metropole de Savoie-Site de Chambery, Chambery, France
🇫🇷
Le Mans Hospital Center, Le Mans, France

and more 23 locations

A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects

Phase 2

Completed

Conditions: Active Non-segmental Vitiligo

Interventions: Drug: PF-06651600
Drug: placebo
Drug: PF06700841
Device: narrow-band UVB phototherapy

First Posted Date: 2018-10-23

Last Posted Date: 2022-03-25

Lead Sponsor: Pfizer

Target Recruit Count: 366

Registration Number: NCT03715829

Locations: 🇺🇸
Advanced Skin and MOHS Surgery Center, c/o TrialSpark, Inc., Chicago, Illinois, United States
🇦🇺
Veracity Clinical Research Pty Ltd, Woolloongabba, Queensland, Australia
🇦🇺
The Royal Melbourne Hospital, Parkville, Victoria, Australia

and more 87 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy